AFMD Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Affimed N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.62 |
| 52 Week High | US$8.95 |
| 52 Week Low | US$2.61 |
| Beta | 2.1 |
| 11 Month Change | -21.20% |
| 3 Month Change | -37.62% |
| 1 Year Change | -43.66% |
| 33 Year Change | -96.24% |
| 5 Year Change | -89.85% |
| Change since IPO | -95.40% |
Recent News & Updates
Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts
Sep 04Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better
Jun 11Recent updates
Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts
Sep 04Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better
Jun 11The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts
Aug 15
Affimed downgraded to hold at Stifel as pipeline lacks development clarity
Oct 10Health Check: How Prudently Does Affimed (NASDAQ:AFMD) Use Debt?
Sep 17Affimed Q2 2022 Earnings Preview
Aug 10Affimed: Preparing For Key Inflection Points
Jun 29Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?
Jun 14Affimed Stock: 3 Points For The Bulls
Apr 09Affimed N.V. (NASDAQ:AFMD) Analysts Just Cut Their EPS Forecasts Substantially
Apr 05Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?
Dec 14Affimed: Preparing For A Bullish 2022
Oct 12Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?
Aug 19Affimed: Current Fall And Future Prospects
Jul 07We Discuss Why Affimed N.V.'s (NASDAQ:AFMD) CEO May Deserve A Higher Pay Packet
Jun 08Need To Know: Analysts Just Made A Substantial Cut To Their Affimed N.V. (NASDAQ:AFMD) Estimates
Apr 20Announcing: Affimed (NASDAQ:AFMD) Stock Increased An Energizing 177% In The Last Three Years
Feb 15Affimed and Roche collaborate to study AFM24 in solid tumors
Feb 03Shareholder Returns
| AFMD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -24.7% | 2.5% | 2.2% |
| 1Y | -43.7% | 16.1% | 31.6% |
Return vs Industry: AFMD underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: AFMD underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| AFMD volatility | |
|---|---|
| AFMD Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AFMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AFMD's weekly volatility has decreased from 15% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 76 | Shawn Leland | www.affimed.com |
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors.
Affimed N.V. Fundamentals Summary
| AFMD fundamental statistics | |
|---|---|
| Market cap | US$42.95m |
| Earnings (TTM) | -US$72.86m |
| Revenue (TTM) | US$5.87m |
7.3x
P/S Ratio-0.6x
P/E RatioIs AFMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AFMD income statement (TTM) | |
|---|---|
| Revenue | €5.64m |
| Cost of Revenue | €0 |
| Gross Profit | €5.64m |
| Other Expenses | €75.61m |
| Earnings | -€69.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.27 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,241.26% |
| Debt/Equity Ratio | 46.9% |
How did AFMD perform over the long term?
See historical performance and comparison